Azithromycin Attenuates Bleomycin-Induced Pulmonary Fibrosis Partly by Inhibiting the Expression of LOX and LOXL-2
Pulmonary fibrosis (PF) is a chronic and progressive process of tissue repair. Azithromycin (AZM) may be beneficial for the treatment of PF because AZM has anti-inflammatory and immune regulatory roles and inhibits remodeling, but the mechanism is not entirely clear. In this study, we established a...
Main Authors: | Xiang Tong, Shijie Zhang, Dongguang Wang, Li Zhang, Jizheng Huang, Tianli Zhang, Hong Fan |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-11-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2021.709819/full |
Similar Items
-
Deglycosylated Azithromycin Attenuates Bleomycin-Induced Pulmonary Fibrosis via the TGF-β1 Signaling Pathway
by: Hao Ruan, et al.
Published: (2021-05-01) -
Triptolide attenuates pulmonary fibrosis by inhibiting fibrotic extracellular matrix remodeling mediated by MMPs/LOX/integrin
by: Weiji Lin, et al.
Published: (2023-10-01) -
The Efficacy and Safety of Azithromycin for Patients with Cystic Fibrosis: A Systematic Review
by: Luh Adi Kusuma Suardiani, et al.
Published: (2022-05-01) -
LOX, but not LOXL2, promotes bone metastasis formation and bone destruction in triple-negative breast cancer
by: Paola Di Mauro, et al.
Published: (2024-02-01) -
LOX-1 Deletion Attenuates Myocardial Fibrosis in the Aged Mice, Particularly Those With Hypertension
by: Xiao Li, et al.
Published: (2021-10-01)